SCHEMBL20855918

SCHEMBL20855918

O=C(O)c1cc(Cl)ncc1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 3/20 0.48
▸ CA2 P00918 3/20 0.48
▸ NAPRT Q6XQN6 1/20 0.44
▸ PTGS2 P35354 2/20 0.42
▸ CA12 O43570 2/20 0.42
▸ CA7 P43166 2/20 0.42
▸ CA9 Q16790 2/20 0.42
▸ CA14 Q9ULX7 2/20 0.42
▸ ALOX5 P09917 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KDR P35968 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ CASP1 P29466 2/20 0.39
▸ HCAR2 Q8TDS4 1/20 0.39
▸ TNF P01375 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ HSPD1 P10809 1/20 0.39
▸ THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL426192 0.83 CA1 (0.44) CA1CA2NAPRTPTGS2CA12
SCHEMBL979398 0.83 NAPRT (0.47) CA1CA2NAPRTALDH1A1KMT2A
SCHEMBL29773884 0.83 NAPRT (0.47) CA1CA2NAPRTALDH1A1KMT2A
SCHEMBL18571881 0.82 HTT (0.41) NAPRTCA9ALDH1A1MEN1KMT2A
SCHEMBL29411268 0.81 ALDH1A1 (0.47) CA1CA2NAPRTCA12CA7
SCHEMBL1300053 0.81 ALDH1A1 (0.47) CA1CA2NAPRTCA12CA7
SCHEMBL5042498 0.79 NAPRT (0.44) CA1CA2NAPRTALDH1A1MEN1
SCHEMBL23854026 0.78 CA1 (0.45) CA1CA2NAPRTPTGS2CA12
SCHEMBL13360236 0.78 CA1 (0.45) CA1CA2NAPRTPTGS2CA12
SCHEMBL18068216 0.78 GABRP (0.47) NAPRTALDH1A1KMT2AKDM4EHCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250230168-A1 AZASPIRO WRN INHIBITORS GILEAD SCIENCES, INC. 2025-07-17 — — US disclosed
WO-2025137640-A1 AZASPIRO WRN INHIBITORS GILEAD SCIENCES, INC. (US) 2025-06-26 — — WO disclosed
CN-116782996-A Tautomeric ligands enable biomimetic C-H hydroxylation under molecular oxygen 斯克里普斯研究学院 2023-09-19 — — CN disclosed
WO-2019063748-A1 ROR-GAMMA INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-04-04 — — WO disclosed
WO-2019063748-A1 ROR-GAMMA INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-04-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250230168-A1 AZASPIRO WRN INHIBITORS WRN, RECQL, BLM CA1 4270/4885CA2 4145/4885NAPRT 1424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback